Navigation Links
Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2008 and Updates 2008 Full Year Guidance
Date:11/10/2008

timing of spending on internal R&D projects.

Based on the revised guidance, the Company expects GAAP net income to be in the range of $133 to $146 million. The Company expects CNI, which adds back the after tax impact of book amortization of intangible assets and the amortization and write off of deferred financing costs, to be in the range of $346 to $359 million. Using 251.0 million Class A common shares, the Company anticipates CNI per share to be in the range of $1.38 to $1.43 for the full year 2008, an increase of $0.08 per share from the guidance given in August of 2008.

Investor Conference Call

The Company is hosting a conference call, open to all interested parties, on Monday, November 10, 2008 beginning at 8:00 AM EST. The number to call within the United States and Canada is (877) 856-1955. Participants outside the United States and Canada should call (719) 325-4798. A replay of the conference call will be available from two hours after the call through midnight EST on November 24, 2008 and can be accessed by dialing (888) 203-1112 from within the United States and Canada or (719) 457-0820 from outside the United States and Canada. The replay ID number is 6395194.

The Company

Warner Chilcott is a leading specialty pharmaceutical company currently focused on the women's healthcare and dermatology segments of the U.S. pharmaceuticals market. The Company is a fully integrated company with internal resources dedicated to the development, manufacturing and promotion of its products. WCRX-F

Forward Looking Statements

This press release contains forward-looking statements, including statements concerning our operations, our anticipated economic performance and financial condition, and our business plans and growth strategy and product development efforts. These statements constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange
'/>"/>

SOURCE Warner Chilcott Limited
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine news :

1. Warner Chilcott Announces Earnings Release Date and Conference Call for Third Quarter 2008 Financial Results
2. House Passes Historic Bill to Protect Kids From Tobacco; Senators Webb & Warner Should Cosponsor Legislation
3. Fitness and Figure Professionals Kirsten Nicewarner and Michelle Adams to Represent GNC at Vails Teva Mountain Games
4. The Oregon Clinic Extends Patient Care Services Across Metro Portland with Time Warner Telecoms Metro Ethernet Service
5. Warner Chilcott Announces Settlement of Securities Litigation
6. LodgeNet Appoints John E. Haire, Former Time Warner Executive, to Board of Directors
7. CooperVision Increases Network Performance While Reducing Costs With Time Warner Telecoms IP VPN
8. Sharing Miracles Television Program to Feature Mountain Climber and Cancer Survivor Sean Swarner
9. Pinstripe Healthcare Group Adds Veteran HR Executive Warner as Client Services Director
10. Warner Chilcott Announces 2008 Financial Guidance
11. Warner Chilcott to Present at the 2008 Wachovia Healthcare Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)...4 CareTech Solutions , an informa... provider for hospitals and health systems, announ...es earned ten awards in the Strategic Communicati...e awards were accepted by CareTech Solutions Execu...Catallo, at the 13th annual Greystone Internet Hea...
(Date:12/4/2009)...an be an effective way to improve moderate to seve... university Karolinska Institutet report. Those wi...ted most from weight loss. , "Our findings sugg... strategy for sleep apnoea in obese men," says Kar...e study. , Sleep apnoea the temporary cessation...
(Date:12/4/2009)... progress has been made over the last 15 years in ... treat epilepsy and its complications. Yet this p...t of the 50 million people around the world, inclu...e United States who have the disorder, , Accordi...American Epilepsy Society (AES), there is an enorm...
(Date:12/4/2009)...hguard (PPM) - certified Dr. Nassery serves local ... and options , Miami Beac...Dr. H.A. Nassery contributes to local athletic com...young athletes and offering the Pure Power Mouthgu...ated Ashley Kimmel, a student at Miami Country Day...
(Date:12/4/2009)...and what 2-D images represent, researchers say , ...eys can recognize photographs of other monkeys the...ces in faces and figure out if they,ve seen them b...ws that capuchin monkeys can decipher the two-dime...hors noted. , The findings, reported by researc...
Breaking Medicine News(10 mins):Health News:CareTech Solutions Web Clients Earn Top Recognition in the Tenth Annual eHealthcare Leadership Awards Competition 2Health News:CareTech Solutions Web Clients Earn Top Recognition in the Tenth Annual eHealthcare Leadership Awards Competition 3Health News:Weight-loss proves effective cure for sleep apnea 2Health News:Weight-loss proves effective cure for sleep apnea 3Health News:Epilepsy patients caught in treatment gap are not getting state-of-the-art care 2Health News:Epilepsy patients caught in treatment gap are not getting state-of-the-art care 3Health News:Epilepsy patients caught in treatment gap are not getting state-of-the-art care 4Health News:Miami Dentist Dr. H.A. Nassery Treats Local Teen Golf Star and Helps Improve Her Performance 2
...hed in the medical journal Thorax a study conclude...culosis infection. The study looked at 2,401 adult...frica. The participants were surveyed about their ... Of 1,309 current smokers or ex-smokers, 1,070...
...ug Administration (FDA) issued a public health adv...ers about the suspended marketing of Tysabri (nata...f multiple sclerosis (MS) which was approved by th...ever, it is believed that the drug has a promising...
...hat is often done as a measure for weight reductio...rt disease. One of the most common procedure...urgery that reduces the size of the stomach and al...s to control obesity through lasting weight loss. ...
...ew discovery regarding the cells that are responsi...searchers from Wake Forest University School of Me... the thalamus area of the brain can slow the relea...tective glutamate receptors in increasing their po...
...er Cancer Institute and collaborating institutions... cancer cells where cancer-related genes may lurk....urnal Cancer Research, the researchers used single...nes were either left out or multiplied over and ov...
...cessfully treat atherosclerosis, the narrowing of ...rmine whether the drugs could also treat a similar...rrowing of the aortic valve in the heart. ...osis. For the study researchers from the United Ki...
Other Medicine News:Health News:Possible location of lung cancer genes found 2
(Date:12/4/2009)..., , WILMINGTON, Del., Dec. 4 /PRNewswire-...ounced that the US Food and Drug Administration (F...tiapine fumarate) Extended Release Tablets as adju...ults with Major Depressive Disorder (MDD). SEROQUE...by the FDA to treat both major depressive disorder...
(Date:12/3/2009)..., , ALISO VIEJO, Calif. and STATE COLLEG...SoftGenetics today announced the signing of an agr... services using SoftGenetics, NextGENe software fo... Ambry. ,, (Logo: http://www.newscom.com/cg...sheidt PhD, Ambry,s CSO said, "Our team at Ambry h...
(Date:12/3/2009)..., , SAN DIEGO, Dec. 3 /PRNewswire-FirstCa...nounced today that it has entered into a new lease...GN ) for approximately 131,000 square feet of addi...ace at The Landmark at Eastview campus in Tarrytow...3. This lease of additional space was completed ap...
Breaking Medicine Technology:US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 2US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 3US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 4US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 5US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 6US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 7US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 8US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 9Ambry Genetics and SoftGenetics Form Exclusive Alliance for Extended Bioinformatics Support for Next Generation Sequencing Projects 2Ambry Genetics and SoftGenetics Form Exclusive Alliance for Extended Bioinformatics Support for Next Generation Sequencing Projects 3BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark 2BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark 3Helix BioPharma Announces 2413 5 Million Private Placement 13855 1Helix BioPharma Announces 2413 5 Million Private Placement 13855 2Researchers design new graphene based nanomaterial with magnetic properties 13854 1Researchers design new graphene based nanomaterial with magnetic properties 13854 2HCC Life Insurance Company Renames Short Term Medical Insurance 56237 1HCC Life Insurance Company Renames Short Term Medical Insurance 56237 2
...TLE, Dec. 6 Results from RESTORE 2, a,placebo-con...estigational,compound retigabine significantly red... refractory partial-onset epilepsy when a 600 mg o...i-epileptic drug (AED) therapy. Prior to,enrollmen... experiencing,seizures despite taking stable doses...
...ADELPHIA, Dec. 6 GlaxoSmithKline (NYSE: GSK ),a... RAISE (RAndomized placebo-,controlled ITP Study w...,(eltrombopag) in adults with chronic immune (idio...eived one or more prior ITP therapies. Patients,re... those on placebo to,maintain platelet counts betw...
Other Medicine Technology:Retigabine Significantly Reduces the Number of Seizures in Adults With Inadequately Controlled Partial-Onset Epilepsy 2Retigabine Significantly Reduces the Number of Seizures in Adults With Inadequately Controlled Partial-Onset Epilepsy 3Retigabine Significantly Reduces the Number of Seizures in Adults With Inadequately Controlled Partial-Onset Epilepsy 4Retigabine Significantly Reduces the Number of Seizures in Adults With Inadequately Controlled Partial-Onset Epilepsy 5GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP 2GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP 3GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP 4GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP 5GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP 6GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP 7GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP 8
ABL80 FLEX Blood Gas Analyzer
Paradigm REAL-Time Insulin Pump and Continuous Glucose Monitoring System
IEC CL40R Centrifuge
IEC CL30R Centrifuge
Medicine Products: